Glaukos Corporation has ignited investor enthusiasm with a powerful trifecta of developments, propelling its stock to impressive gains. The equity advanced nearly 18% within a single week, fueled by record-breaking financial results, an upward revision of its financial outlook, and a significant regulatory approval from the U.S. Food and Drug Administration. The central question for the market is whether this powerful momentum is sustainable.
FDA Green Light Opens New Market
A pivotal development occurred on October 20, when the FDA granted approval for Epioxa™. This treatment is recognized as the first and only incision-free therapy for keratoconus. The company has scheduled its market launch for the first quarter of 2026, with a wholesale price set at $78,500. This authorization has the potential to catapult Glaukos into an entirely new competitive sphere and revenue stream.
Quarterly Earnings Shatter Projections
The company’s financial report for the third quarter of 2025, released on October 29, far exceeded market expectations. Glaukos posted an adjusted loss per share of ($0.16), a significant improvement over analyst forecasts that ranged from ($0.27) to ($0.26). The revenue performance was even more striking, climbing to a record $133.5 million and soundly beating projections of approximately $122.5 million.
Key performance indicators from the quarter include:
* Year-Over-Year Revenue Growth: 38%
* U.S. Glaucoma Sales: A substantial 57% increase to $80.8 million
* iDose® TR Revenue: Contributed $40 million in the quarter
* Non-GAAP Gross Margin: Improved to 84%
Should investors sell immediately? Or is it worth buying Glaukos?
Bolstered by these results, management raised its full-year 2025 revenue guidance to a range of $490 million to $495 million. Furthermore, the company provided its first outlook for 2026, forecasting revenue between $600 million and $620 million.
Analyst Community Fuels the Rally
The positive news flow triggered immediate and bullish responses from Wall Street analysts, who issued a series of raised price targets and upgraded ratings:
- Goldman Sachs and Needham maintained “Buy” ratings with price targets around $120.
- BTIG Research lifted its price objective from $104 to $116.
- Wells Fargo upgraded the stock to “Overweight” and increased its target from $92 to $120.
- JPMorgan Chase reaffirmed an “Overweight” rating with a $120 price target.
Despite the overwhelming optimism, a note of caution remains. An upcoming meeting of the Medicare Advisory Committee on November 12 holds the potential to influence reimbursement terms for the iDose product. This very concern was responsible for a temporary 12% drop in the share price at the end of October.
As the stock battles to consolidate gains above the $100 mark, investors are left to ponder whether Glaukos can maintain its explosive ascent or if a period of correction is on the horizon.
Ad
Glaukos Stock: Buy or Sell?! New Glaukos Analysis from February 1 delivers the answer:
The latest Glaukos figures speak for themselves: Urgent action needed for Glaukos investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 1.
Glaukos: Buy or sell? Read more here...
